CU6 1.41% $6.46 clarity pharmaceuticals ltd

Ann: First patient dosed in Phase III prostate cancer trial, page-15

  1. 1,607 Posts.
    lightbulb Created with Sketch. 380
    We got clues over 12 months ago that there was something different about this stock. While everything else in spec biotech continued to tank, CU6 was holding and beginning to rise and it was one of the worst periods for spec biotech in history. That’s about the most bullish signal you can get. Since then there’s be nothing but great result after great result and more great results at a cracking pace.
    I wish more people knew about this stock in retail.

    Merry Christmas .

 
watchlist Created with Sketch. Add CU6 (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.